Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, ...

Bio-Rad Laboratories, Inc. is an American multinational manufacturer and distributor of life science research and clinical diagnostic products. The company was founded in 1952 in Berkeley, California, ...

Bio-Rad Laboratories Inc (NYSE:BIO) is set to release its Q2 2025 earnings on Jul 31, 2025. The consensus estimate for Q2 2025 revenue is $615.11 million, and the earnings are expected to come in at ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

Throughout the last three months, 5 analysts have evaluated Bio-Rad Laboratories (NYSE:BIO), offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

I like the look of Bio-Rad. Q119 EPS of $1.65 beat expectations by $0.5. GAAP EPS of $28.74 gives a P/E ratio of 10.8 - very low for the sector. This is a sector with high barriers to entry in which ...

Bio-Rad Laboratories stock (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 48% fall this year, significantly underperforming the broader S&P500 index, down 24 ...

) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Bio-Rad Laboratories as such a stock due to the following factors: BIO has an average ...

The stock price of Bio-Rad Laboratories (NYSE: BIO), a life science research and clinical diagnostic products company, has seen a 10% rise over the last twenty-one trading days, while it is up 30% ...

There's a strong case to be made for both companies, but which one is a better investment? There are plenty of interesting healthcare stocks to choose from on the market right now. Whether they be ...